讲师

 1.X. Zhang, Vallesamidine and schizozygane alkaloids: rearranged monoterpene indole alkaloids and synthetic endeavours. Nat. Prod. Rep.2024, 41, 784.

 2.K. Wang‡, X. Zhang‡, Y. Cheng, Z. Qi, K. Ye, K. Zhang, S. Jiang, Y. Liu, Y. Xiao, T. Wang, Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. J. Med. Chem.2023, 66, 16807.

3.T. Wang‡, K. Wang‡, Y. Zhang, K.Zhang, S. Cai, S. Jiang*, Y. Xiao*, X. Zhang*, Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V‐Domain Ig Suppressor of T‐Cell Activation (VISTA). J. Med. Chem.2023, 66, 11881.

4.K. Zhang, T, Wang, M. Li, M. Liu, H. Tang, L. Wang, K. Ye, J. Yang, S. Jiang, Y. Xiao, Y. Xie*, M. Lu*, X.Zhang*, Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). Eur. J. Med. Chem.2023, 257, 115487.

6.X. Zhang, J. C. Anderson*, A Divergent Synthetic Route to the Vallesamidine and Schizozygine Alkaloids: Total Synthesis of (+)-Vallesamidine and (+)-14,15-Dehydrostrempeliopine. Angew. Chem. Int. Ed.2019, 58, 18040.

章翔宇
讲师
院系：生物医学工程与诊断药学系
招生方向：制药工程
实验室：实验楼B603
电子邮箱：1020202601@cpu.edu.c
办公室：实验楼B602
个人简介

章翔宇，suncitygroup太阳集团生物医学工程与诊断药学系讲师，硕士研究生导师。博士毕业于英国伦敦大学学院（University College London，UCL），师从Jim Anderson教授（FRSC）。2020年加入suncitygroup太阳集团从事教学科研工作。

研究方向

  1. 复杂天然产物和手性药物的全合成研究和工艺开发，聚焦具有多种药理活性的复杂生物碱、前列腺素类高活性药物的工艺研究与创新衍生；

  2. 靶向药物/分子探针的设计、合成与生物学活性评价

承担项目情况

2021年获江苏省“双创博士”，主持国家自然科学基金青年项目一项（2021-2023）、参与面上项目一项，中央高校基本科研业务经费重点项目一项（2022-2023）；

在Angew. Chem. Int. Ed. (IF 16.6)、 Nat. Prod. Rep. (IF 11.9)、 J. Med. Chem. (IF 7.3)、Eur. J. Med. Chem. (IF 6.7) 等专业学术期刊发表学术论文多篇，专利转让1项。

代表性科研成果

 1.X. Zhang, Vallesamidine and schizozygane alkaloids: rearranged monoterpene indole alkaloids and synthetic endeavours. Nat. Prod. Rep.2024, 41, 784.

 2.K. Wang‡, X. Zhang‡, Y. Cheng, Z. Qi, K. Ye, K. Zhang, S. Jiang, Y. Liu, Y. Xiao, T. Wang, Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. J. Med. Chem.2023, 66, 16807.

3.T. Wang‡, K. Wang‡, Y. Zhang, K.Zhang, S. Cai, S. Jiang*, Y. Xiao*, X. Zhang*, Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V‐Domain Ig Suppressor of T‐Cell Activation (VISTA). J. Med. Chem.2023, 66, 11881.

4.K. Zhang, T, Wang, M. Li, M. Liu, H. Tang, L. Wang, K. Ye, J. Yang, S. Jiang, Y. Xiao, Y. Xie*, M. Lu*, X.Zhang*, Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). Eur. J. Med. Chem.2023, 257, 115487.

6.X. Zhang, J. C. Anderson*, A Divergent Synthetic Route to the Vallesamidine and Schizozygine Alkaloids: Total Synthesis of (+)-Vallesamidine and (+)-14,15-Dehydrostrempeliopine. Angew. Chem. Int. Ed.2019, 58, 18040.